ANI Pharmaceuticals Inc (ANIP) EPS Estimated At $0.90

October 14, 2017 - By Michael Collier

 ANI Pharmaceuticals Inc (ANIP) EPS Estimated At $0.90
Investors sentiment decreased to 1.06 in Q2 2017. Its down 0.34, from 1.4 in 2017Q1. It dropped, as 20 investors sold ANI Pharmaceuticals Inc shares while 42 reduced holdings. 17 funds opened positions while 49 raised stakes. 6.39 million shares or 4.42% more from 6.12 million shares in 2017Q1 were reported.
Ativo Cap Limited Liability Com invested in 0.33% or 26,005 shares. Icon Advisers owns 8,700 shares for 0.03% of their portfolio. 12,990 are owned by Etrade Ltd Llc. Kbc Gru Nv has invested 0.01% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Winslow Evans & Crocker Incorporated owns 8 shares. Sei Com has 1,157 shares for 0% of their portfolio. Nomura stated it has 0.02% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Blackrock stated it has 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Farmers And Merchants Invs has 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 131 shares. Parametric Associate Lc invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Lpl Finance Limited Liability Co stated it has 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). 16,243 are owned by Goldman Sachs. Legal & General Gp Plc holds 0% or 14,581 shares in its portfolio. Vanguard Group Incorporated has invested 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Geode Cap Ltd Liability owns 65,347 shares for 0% of their portfolio.

Analysts expect ANI Pharmaceuticals Inc (NASDAQ:ANIP) to report $0.90 EPS on November, 2.They anticipate $0.12 EPS change or 11.76 % from last quarter’s $1.02 EPS. ANIP’s profit would be $10.47 million giving it 16.70 P/E if the $0.90 EPS is correct. After having $0.88 EPS previously, ANI Pharmaceuticals Inc’s analysts see 2.27 % EPS growth. The stock increased 10.84% or $5.88 during the last trading session, reaching $60.11. About 451,268 shares traded or 391.96% up from the average. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 0.02% since October 14, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. ANI Pharma had 16 analyst reports since July 31, 2015 according to SRatingsIntel. TH Capital downgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Wednesday, February 22 to “Neutral” rating. Oppenheimer maintained the stock with “Outperform” rating in Friday, July 31 report. The firm earned “Perform” rating on Tuesday, July 19 by Oppenheimer. As per Friday, August 5, the company rating was maintained by Oppenheimer. Standpoint Research downgraded the shares of ANIP in report on Tuesday, May 24 to “Hold” rating. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Neutral” rating given on Tuesday, August 4 by TH Capital. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Buy” rating by Canaccord Genuity on Wednesday, August 9. The firm has “Buy” rating by Roth Capital given on Monday, September 28. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Strong Buy” rating given on Thursday, June 23 by Raymond James. On Monday, September 28 the stock rating was upgraded by TH Capital to “Buy”.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has market cap of $699.59 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 133.39 P/E ratio. The Firm focuses on areas, including controlled substances, anti-cancer , hormones and steroids, and complex formulations.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: Seekingalpha.com which released: “The Case For A Pending Partnership Between Ani Pharmaceuticals And AbbVie” on June 19, 2017, also Prnewswire.com with their article: “ANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth …” published on August 08, 2017, Prnewswire.com published: “ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate …” on June 20, 2017. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: Seekingalpha.com and their article: “ANI Pharmaceuticals: Coming Back From Oversold Levels” published on March 28, 2017 as well as Seekingalpha.com‘s news article titled: “ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of …” with publication date: August 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com